Mixed results for new NHL therapies
Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.
Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.
Professor Peter Johnson (Southampton, UK) tells us what’s new with response-adapted therapy and what are the benefits to patients.
By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.
Professor Mohamad Mohty (Paris), Professor Sagar Lonial (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.
by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.
Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.
by Gary Finnegan: Keytruda (pembrolizumab) has been recommended by the European Medicines Agency (EMA) as monotherapy for the treatment of adult patients with advanced melanoma that cannot be… read more.
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
by Bruce Sylvester: Treatment of advanced melanoma with a combination of nivolumab (Opdivo™) and ipilimumab (Yervoy™) or with nivolumab alone increases progression-free survival over ipilimumab monotherapy, researchers reported… read more.
by Bruce Sylvester: Pembrolizumab (Keytruda®), an anti-PD-1 antibody immunotherapy has shown efficacy in one fourth of patients with recurrent or metastatic head and neck cancer, researchers reported on… read more.
by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.
by Thomas R. Collins: The use of chimeric antigen receptor T-cells — in which a patient’s own T cells are modified to fight cancer cells — is showing good results… read more.